Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout
Selecta Biosciences, Inc. (SELB)
Last selecta biosciences, inc. earnings: 3/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
selectabio.com/investors-media/investor-relations
Company Research
Source: GlobeNewswire
– Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing head-to-head COMPARE trial and in future Phase 3 clinical studies – – Enrollment in the COMPARE trial expected to complete by the end of 2019; interim data to be reported in Q1 2020, and top-line statistical superiority data expected by mid-2020 – WATERTOWN, Mass., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced new data from their Phase 2 dose-ranging study evaluating SEL-212, a combined therapy of ImmTOR + pegadricase for the treatment of chronic refractory gout. Results reinforce that, in the five monthly combination cohorts, SEL-212 is effective in reducing incidence of gout flares and supports dose selection in the head-to-head COMPARE clinical trial a
Show less
Read more
Impact Snapshot
Event Time:
SELB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SELB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SELB alerts
High impacting Selecta Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics